Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia New study further validates Noxopharm’s cancer pipeline Highlights • Proof-of-principle that Noxopharm technology helps initiate immune response with normally ‘immune -...
New study further validates Noxopharms cancer pipeline
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
- Noxopharm progresses US regulatory strategy
Later from Noxopharm
- New preclinical data supports immuno-oncology approach
- Appendix 4E - Preliminary Financial Report
- Novel oligonucleotides data presented at Options Conference
- Investor Presentation September 2026
- SOF-SKN to progress to extension study in CLE patients
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm